The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 566.4 million by 2020. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.
The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand.
The global market for corticosteroid is valued at over USD 125.0 million in 2013. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.
For PDF sample Copy or More Details please visit link @:
http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
TPO-RA is likely to witness substantial growth, growing at a CAGR of over 9.0% from 2014 to 2020 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
North America accounted for a majority share in 2013 due to the rising occurrence of diseases coupled with the presence of high treatment rates, favorable government initiatives, and funding programs. North America had a share of over 40% of the global ITP market by revenue in 2013 and is expected to witness high demand over the forecast period.
Europe accounted for the second-largest market share in 2013. This trend is projected to continue over the forecast period due to high usage rates of products along with government initiatives granting special status to orphan drugs factors.
Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.
Some of the major players in the industry are and GlaxoSmithKline Plc., Hoffman-L Roche, Amgen Inc., and Grifols Biologicals Inc. The companies make significant R&D investments aimed at new product development by taking advantage of incentives offered under the pertinent government regulations.
To request research report sample copy with TOC please visit @: https://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics/request/rs1
Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 - 2020)
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Anti-D Immunoglobulin
• Thrombopoietin Receptor Agonists (TPO-RA)
• Others
ITP Therapeutics Regional Outlook (Revenue, USD Million, 2012 - 2020)
• North America
o The U.S.
o Mexico
• Europe
o Germany
o The U.K.
• Asia Pacific
o India
o Japan
o China
• RoW
o Brazil
For Inquire before buying please visit @: https://www.grandviewresearch.com/inquiry/790/ibb
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.